Condition: Atrial Fibrillation

A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation

Location(s): Jacksonville (Headquarters)

Condition: Atrial Fibrillation